Organon Brasil company information, Employees & Contact Information

Organon Appoints Company Executive Joseph Morrissey as Interim CEO citybiz

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025 Business Wire

Organon (OGN): Company Profile, Stock Price, News, Rankings Fortune

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Yahoo Finance

UNFPA Thailand Joins Organon Thailand to Empower Women to Shape Their Own Future Khaosod English

Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued Stock Titan

Organon Reports Results for the First Quarter Ended March 31, 2025 Business Wire

Organon Canada Announces the Availability of NDUVRA® (Tapinarof Cream), 1%, for the Topical Treatment of Plaque Psoriasis in Adults PR Newswire Canada

PLAS, Organon spotlight heart health, urge early action against high cholesterol Inquirer.net

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors Yahoo Finance

(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Business Wire

Major Breakthrough: AAD Guidelines Endorse Steroid-Free VTAMA Cream for 26M Eczema Patients Stock Titan

UNFPA, Organon and MIT Solve announce the 14 winners of the 4HerPower Challenge United Nations Population Fund

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% GlobeNewswire

Organon calls for greater awareness on Cardiovascular Disease Prevention for women Inquirer.net

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 Business Wire

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection Business Wire

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) Business Wire

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA Business Wire

Organon Launches as New Women’s Health Company Business Wire

Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data Center for Biosimilars

Making Organon’s operating model fit for the future. Accenture

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator Business Wire

Adults, children maintain mild AD during treatment-free period follow Vtama cream 1% Healio

Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist Business Wire

Vtama receives FDA approval for atopic dermatitis Healio

Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD HCPLive

Organon: It's Darkest Before The Dawn (NYSE:OGN) Seeking Alpha

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia Business Wire

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024 The AI Journal

FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis AJMC

Here for Her Health: Introducing Organon to the World The Shorty Awards

FDA Approves Tapinarof 1% Cream for Adult, Pediatric Patients with Atopic Dermatitis HCPLive

Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy Business Wire

Organon Juan Camilo Arjona Ferreira, M.D., as CMO and Charlotte Owens, MD, FACOG, as Head of Medical Affairs and Outcomes Research citybiz

Organon to Acquire Forendo Pharma Business Wire

FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA Business Wire

FDA pushes PDUFA date of tapinarof cream, 1% for atopic dermatitis to 2025 Contemporary Pediatrics

EMA Validates Filings for Denosumab Biosimilar Candidate HLX14 for Osteoporosis OncLive

ADDING MULTIMEDIA Organon Launches as New Global Women’s Health Company Business Wire

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued (OGN) Seeking Alpha

Organon & Co: Cost Takeout Catalysts, Initiate Strong Buy Seeking Alpha

Organon Acquires Forendo Pharma citybiz

Tapinarof cream 1% demonstrates positive long-term results for atopic dermatitis in patients 2 years and up Contemporary Pediatrics

Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield (OGN) Seeking Alpha

Two More Pairs of Denosumab Biosimilars Enter US Market Center for Biosimilars

Organon Announces Pricing of $1.0 Billion Senior Notes Offering The AI Journal

Organon Canada Announces the Availability of NDUVRA® (Tapinarof Cream), 1%, for the Topical Treatment of Plaque Psoriasis in Adults Yahoo

FDA approves tapinarof cream, 1% for atopic dermatitis patients 2 years and up Contemporary Pediatrics

FDA Extends Organon's VTAMA Review by 3 Months; $125M Revenue Target Still on Track Stock Titan

System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology Business Wire

Organon Acquires Contraceptive Products, Marvelon and Mercilon citybiz

Organon and ObsEva Enter Global License Agreement to GlobeNewswire

Organon & Co. (OGN) Stock Price, News & Analysis MarketBeat

Organon underscores the importance of contraceptive education on World Contraception Day Inquirer.net

Organon announces commitment to accelerating advancements in women's health at EXPO 2020 PR Newswire UK

Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer PR Newswire Canada

Innovating for women’s health: Addressing PPH with the JADA® System Inquirer.net

Organon Canada launches Ontruzant®, a biosimilar of the reference biologic Herceptin®, providing patients in Canada with certain breast and gastric cancers with an additional therapeutic option at a lower cost PR Newswire Canada

Organon Canada Launches as New Women's Health Company PR Newswire Canada

Organon Canada reinforces the need to raise awareness and access for contraception methods with nearly half of pregnancies unplanned PR Newswire Canada

European Commission (EC) Approves Henlius and Organon’s BILDYOS ® (denosumab) and BILPREVDA ® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Via TT

Organon Acquires Contraceptive Products, Marvelon ® and Mercilon ® , in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam NTB Kommunikasjon

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Tirto.id

Report reveals the impact of unintended pregnancies Hospital + Healthcare

A Synthetic Antithrombin III Binding Pentasaccharide Is Now a Drug! What Comes Next? Wiley Online Library

A Synthetic Antithrombin III Binding Pentasaccharide Is Now a Drug! What Comes Next? Wiley Online Library